This guideline by the European Medicins Agancy, Committee for Medicinal Products for Human Use (CHMP), was drafted in 2011 and outlines general recommendations on acceptable frameworks for handling missing data. It is important that an analysis is provided for which it is judged that it is unlikely that it is biased in favour of the experimental treatment (i.e. the method can be considered ‘conservative’).